Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin PET/CT for imaging of paragangliomas
2024-516755-40-00Phase 2Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exenatide in Paraganglioma (PGL), sponsored by Radboud University Medical Center. Primary endpoint: Detection rate of paragangliomas using 68Ga-exendin-4 PET/CT. Planned start Sep 2024; status: authorised.
02
Drugs
exenatide
03
Conditions
Paraganglioma (PGL)
Beyond the preview
Go deeper on 2024-516755-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516755-40-00.